Evelo Biosciences
About Evelo Biosciences
The gut is a central organ of the immune system which controls immunity and inflammation through its interactions with microbes in the small intestine
We are developing a new class of oral biologic therapies that engage immune cells in the small intestine to transmit effects throughout the body
Modulation of this “gut-body network" has therapeutic potential in many major diseases
For general inquiries contact: info@evelobio.com
For media inquiries contact: media@evelobio.com
For investor inquiries contact: ir@evelobio.com
NASDAQ EVLO
97 articles with Evelo Biosciences
-
Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock
5/25/2022
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 54,246,358 shares of common stock (the “Shares”) at a purchase price of $1.46 per share, resulting in gross proceeds of $79.2 million.
-
Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
5/12/2022
Evelo Biosciences, Inc. reported financial results and business highlights for the first quarter 2022.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors
4/21/2022
Evelo Biosciences, Inc. announced that John Maraganore, Ph.D., founder and longtime former CEO of Alnylam Pharmaceuticals, and Tassos Gianakakos, the longtime former CEO of MyoKardia, have joined Evelo as strategic advisors.
-
Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs
4/14/2022
Evelo Biosciences, Inc. provided an update on the progress of its lead program in inflammation, EDP1815, and announced it will put the EDP1867 program on hold following completion of a Phase 1 clinical trial.
-
Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors
4/6/2022
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of Jose-Carlos Gutiérrez-Ramos, Ph.D., and Tonya Williams, J.D., to its Board of Directors.
-
The 2022 American Academy of Dermatology Annual Meeting saw several milestones for treatment explorations for inflammatory diseases. Here is some of the major news:
-
Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting
3/26/2022
Evelo Biosciences, Inc. presented a late-breaking oral abstract on data from a Phase 2 trial of EDP1815 in psoriasis at the 2022 American Academy of Dermatology Annual Meeting, being held March 25-29 in Boston, Massachusetts.
-
Evelo Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
3/24/2022
Evelo Biosciences, Inc., a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, reported financial results and business highlights for the fourth quarter and full year 2021.
-
Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
3/17/2022
Evelo Biosciences, Inc. (Nasdaq:EVLO), today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its fourth quarter and full year 2021 financial results and discuss business highlights.
-
Evelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of Psoriasis and Potential of SINTAX Medicines
3/7/2022
Evelo Biosciences, Inc. announced that it will host a virtual event titled, “The Future: A no regrets treatment for all stages of psoriasis and broader inflammatory disease.” The event will be held virtually on Friday, March 11, 2022, beginning at 8:00 a.m. ET.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
Evelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference
3/2/2022
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that Simba Gill, Ph.D., Chief Executive Officer of Evelo, will participate in a panel discussion titled “GI/Microbiome” at the Cowen 42nd Annual Health Care Conference.
-
Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis
2/28/2022
Evelo Biosciences, Inc., a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, announced data from the post-treatment follow-up of its Phase 2 trial of EDP1815 in mild and moderate psoriasis which included durable and deeper clinical responses.
-
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis
2/17/2022
Evelo Biosciences, Inc. today announced that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis.
-
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial
2/7/2022
Evelo Biosciences, Inc. today announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate psoriasis.
-
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases
1/17/2022
Evelo Biosciences, Inc. today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis.
-
Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts
1/4/2022
Evelo Biosciences, Inc., a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, announced its strategic priorities and upcoming catalysts for 2022.
-
Evelo Biosciences Added to Nasdaq Biotechnology Index
12/14/2021
Evelo Biosciences, Inc. today announced that the Company has been added to the NASDAQ Biotechnology Index ® (Nasdaq: NBI), effective prior to market open on December 20, 2021.